Based on this study, the US Food and Drug Administration (FDA) granted accelerated approval of pembrolizumab for treatment of GC patients, whose tumours express PD‐L1, as determined by an FDA‐approved test.20 This evidence concerns the gene CD274 and gastric cancer.